

# Duvelisib

**Catalog No: tcsc0888**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

**Size:** 1g

**Size:** 2g



## Specifications

**CAS No:**

1201438-56-3

**Formula:**

$C_{22}H_{17}ClN_6O$

**Pathway:**

PI3K/Akt/mTOR

**Target:**

PI3K

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 41$  mg/mL (98.35 mM)

**Alternative Names:**

IPI-145;INK1197

**Observed Molecular Weight:**


416.86

**Product Description**

Duvelisib is a selective **p100δ** inhibitor with IC<sub>50</sub> of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.

IC50 & Target: IC50: 2.5 nM (p110δ), 27.4 nM (p110γ), 85 nM (p110β), 1602 nM (p110α)<sup>[2]</sup>

***In Vitro:*** PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!